Search Results

• • 12 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in Ethiopian patients

  Authors:Getnet Yimer, Marcus Gry, Wondwossen Amogne, Eyasu Makonnen, Abiy Habtewold, Zelalem Petros, et al.From:PLoS ONE (Vol. 9, Issue 4) Peer-Reviewed

  Apr. 20146,538 words Report 1650LObjectives: To evaluate the incidence, type, severity and predictors of antiretroviral and/or anti-tuberculosis drugs induced liver injury (DILI). Methods: A total of 1,060 treatment naive patients were prospectively...

• Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations

  Authors:Eliford Ngaimisi, Abiy Habtewold, Omary Minzi, Eyasu Makonnen, Sabina Mugusi, Wondwossen Amogne, et al.From:PLoS ONE (Vol. 8, Issue 7) Peer-Reviewed

  July 5, 20136,847 words Clinical report 1550LObjectives We evaluated the importance of ethnicity and pharmacogenetic variations in determining efavirenz pharmacokinetics, auto-induction and immunological outcomes in two African populations. Methods ART...

• [beta]-defensin genomic copy number is associated with HIV load and immune reconstitution in sub-Saharan African

  Authors:Robert J. Hardwick, Wondwossen Amogne, Sabina Mugusi, Getnet Yimer, Eliford Ngaimisi, Abiy Habtewold, et al.From:Journal of Infectious Diseases (Vol. 206, Issue 7) Peer-Reviewed

  Oct. 1, 2012 Report

   Citation Only

• Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients

  Authors:Getnet Yimer, Nobuhisa Ueda, Abiy Habtewold, Wondwossen Amogne, Akira Suda, Klaus-Dieter Riedel, et al.From:PLoS ONE (Vol. 6, Issue 12) Peer-Reviewed

  Dec. 6, 20116,016 words Clinical report 1480LBackground Implication of pharmacogenetic variations and efavirenz pharmacokinetics in concomitant efavirenz based antiviral therapy and anti-tubercular drug induced liver injury (DILI) has not been yet studied. We...

• Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: a prospective cohort study

  Authors:Hanna Nylen, Abiy Habtewold, Eyasu Makonnen, Getnet Yimer, Leif Bertilsson, Jurgen Burhenne, et al.From:Medicine (Vol. 95, Issue 34) Peer-Reviewed

  Aug. 23, 2016 Article

   Citation Only

• Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/[mu]L: TB-HAART Study, a Randomized Clinical Trial

  Authors:Wondwossen Amogne, Getachew Aderaye, Abiy Habtewold, Getnet Yimer, Eyasu Makonnen, Alemayhu Worku, et al.From:PLoS ONE (Vol. 10, Issue 5) Peer-Reviewed

  May 12, 20156,827 words Clinical report 1500LBackground Given the high death rate the first two months of tuberculosis (TB) therapy in HIV patients, it is critical defining the optimal time to initiate combination antiretroviral therapy (cART). Methods A...

• Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study.

  Authors:Hanna NylȨn, Abiy Habtewold, Eyasu Makonnen, Getnet Yimer, Leif Bertilsson, Jȭrgen Burhenne, et al.From:Medicine (Vol. 95, Issue 32) Peer-Reviewed

  Aug. 1, 2016423 words Report, Author abstr...

   Abstract Only

• Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study

  Authors:Abiy Habtewold, Eyasu Makonnen, Wondwossen Amogne, Getnet Yimer, Getachew Aderaye, Leif Bertilsson, et al.From:Pharmacogenomics (Vol. 16, Issue 10) Peer-Reviewed

  July 20159,462 words Report 1810LAuthor(s): Abiy Habtewold aff1 aff2 , Eyasu Makonnen aff2 , Wondwossen Amogne aff3 aff4 , Getnet Yimer aff1 aff2 , Getachew Aderaye aff3 , Leif Bertilsson aff1 , Jürgen Burhenne aff5 , Eleni Aklillu [*] aff1 Keywords...

• Anti-Tuberculosis Therapy-Induced Hepatotoxicity among Ethiopian HIV-Positive and Negative Patients

  Authors:Getnet Yimer, Getachew Aderaye, Wondwossen Amogne, Eyasu Makonnen, Eleni Aklillu, Lars Lindquist, et al.From:PLoS ONE (Vol. 3, Issue 3) Peer-Reviewed

  Mar. 19, 20083,971 words Article 1700LBackground To assess and compare the prevalence, severity and prognosis of anti-TB drug induced hepatotoxicity (DIH) in HIV positive and HIV negative tuberculosis (TB) patients in Ethiopia. Methodology/Principal...

• Patterns of Anthracycline-Based Chemotherapy-Induced Adverse Drug Reactions and Their Impact on Relative Dose Intensity among Women with Breast Cancer in Ethiopia: A Prospective Observational Study.

  Authors:Diriba Alemayehu Gadisa, Mathewos Assefa, Gosaye Mekonen Tefera, and Getnet YimerFrom:Journal of OncologyPeer-Reviewed

  Mar. 31, 20207,390 words Clinical report 1530LBackground. The breast cancer chemotherapy leads to diverse aspects of noxious or unintended adverse drug reactions (ADRs) that cause the relative dose intensity (RDI) reduced to below optimal (i.e., if the percentage of...

• Efficacy and Safety of 'Fixed Dose' versus 'Loose' Drug Regimens for Treatment of Pulmonary Tuberculosis in Two High TB-Burden African Countries: A Randomized Controlled Trial

  Authors:Abraham Aseffa, Joseph N. Chukwu, Mahnaz Vahedi, Emmanuel N. Aguwa, Ahmed Bedru, Tesfamariam Mebrahtu, et al.From:PLoS ONE (Vol. 11, Issue 6) Peer-Reviewed

  June 20, 20165,548 words Report 1390LBackground There are limited data on the performance of the use of fixed-dose combination (FDC) TB drugs when used under programmatic settings in high TB-endemic countries. We evaluated the efficacy and safety of FDC...

• [beta]-defensin genomic copy number is associated with HIV load and immune reconstitution in sub-Saharan Africans

  Authors:Robert J. Hardwick, Wondwossen Amogne, Sabina Mugusi, Getnet Yimer, Eliford Ngaimisi, Abiy Habtewold, et al.From:Journal of Infectious Diseases (Vol. 206, Issue 7) Peer-Reviewed

  Oct. 1, 2012 Report

   Citation Only